RMD stock forecast: what analysts expect
Wall Street analysts covering ResMed Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $247.20 — +9.4% versus the last price of $226.00. Targets reflect analyst opinion, not a guarantee.
RMD historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in RMD.
RMD annual returns by year
Congress trading in RMD
4 members of Congress have disclosed trading RMD — 1 purchase and 4 sales worth an estimated $474,000. Most recent disclosure: Jun 4, 2025.
Insider activity in RMD
RMD's own executives and directors have made 0 open-market purchases ($0) and 4 sales ($4.9M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 7, 2026.
| Aug 7, 2026 | Farrell Michael J. | Chairman and CEO | Sell | $1.0M |
| Aug 5, 2026 | Farrell Peter C | Director | Sell | $1.8M |
| Jul 7, 2026 | Farrell Michael J. | Chairman and CEO | Sell | $1.1M |
| Jun 8, 2026 | Farrell Michael J. | Chairman and CEO | Sell | $968,064 |
About ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
RMD Key Statistics
RMD in plain English
- P/E ratio (21.5) — how many dollars you pay for each $1 of RMD's yearly profit. That's a fairly normal range.
- ROE (24.27%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (26.95%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (1.17%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
RMD stock: frequently asked questions
What is ResMed Inc.'s stock price today?
ResMed Inc. (RMD) last traded at $226.00 on the NYSE. Over the past 52 weeks the stock has traded between $180.27 and $293.81.
Is RMD stock a buy or a sell?
Wall Street analysts' consensus rating on RMD is "Buy", with an average 12-month price target of $247.20 — about +9.4% versus the current price of $226.00. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in RMD 10 years ago be worth today?
A $1,000 investment in ResMed Inc. made 10 years ago would be worth about $3,775 today (dividends reinvested) — a total return of 277%, or 14.2% per year.
Does RMD pay a dividend?
Yes. ResMed Inc. currently pays a dividend yielding about 1.17% per year at today's share price.
What is RMD's P/E ratio?
RMD trades at a trailing price-to-earnings ratio of 21.5, and 17.1 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade RMD stock?
Yes — 4 members of Congress have disclosed trades in RMD under the STOCK Act, totaling 1 purchases and 4 sales worth an estimated $474,000.
What is ResMed Inc.'s ticker symbol?
ResMed Inc. trades under the ticker symbol RMD on the NYSE.
Compare RMD with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.